RT Journal Article
SR Electronic
T1 Neutrophil gelatinase-associated lipocalin and Fibrinogen-to-albumin ratio are indicators of nephropathy in adult steady state sickle cell disease patients: A multicenter case-control study in Ghana
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.10.14.24315440
DO 10.1101/2024.10.14.24315440
A1 Twumasi, Stephen
A1 Odame Anto, Enoch
A1 Obirikorang, Christian
A1 Kobina Dadzie Ephraim, Richard
A1 Sackey, Benedict
A1 Paintsil, Vivian
A1 Owusu Ansah, Richard
A1 Effah, Alfred
A1 Adofo Ayirebi, Allwell
A1 Opoku, Angela
A1 Yawson Scott, Godfred
A1 Osei, Leslie
A1 Duku, Joyce
A1 Asafo Adjei, Emmanuel
A1 Antwi Boateng, Lilian
YR 2024
UL http://medrxiv.org/content/early/2024/10/16/2024.10.14.24315440.abstract
AB Background Progressive renal failure is one of the main complications in sickle cell disease. Neutrophil Gelatinase-Associated Lipocalin (NGAL) is present in gelatinase/tertiary granules of neutrophils and it is a relatively newly recognized marker of nephropathy. Fibrinogen increases and albumin decreases in inflammatoy conditions like SCD. This study investigated the diagnostic roles of NGAL and fibrinogen-to-albumin ratio in steady state adult sickle cell disease patients.Methods In this study, 104 sickle cell disease participants and 51 healthy subjects were analysed. Participants’ information was thoroughly documented using a structured questionnaire and patient case records. To evaluate the hematobiochemical parameters, 5ml of venous blood was drawn from each participant and a clean catch of mid-stream urine was collected from each participant. Subjects with sickle cell disease were further classified as SCD nephropathy and SCD non- nephropathy subjects based on reduced estimated Glomerular Filtration Rate (eGFR) and microalbuminuria.Results Prevalence of nephropathy was 32.7% among adult steady state SCD patients. Significant high levels of Urine Albumin-to-Creatinine Ratio (UACR), NGAL and fibrinogen-to-albumin ratio (FAR) were seen in SCD patients with nephropathy compared to those without nephropathy (p<0.001). NGAL levels significantly increased along with increased urine albumin-to-creatinine ratio (r=0.28, p<0.005) in both SCD with nephropathy and those without nephropathy. There was a significant negative correlation between creatinine (r=-0.90, p<0.0005), urea (r=-0.50, p<0.0005) and eGFR in SCD subjects. Similarly, a significant negative relationship existed between UACR and eGFR (r=-0.34, p<0.0005). Creatinine also had a significant positive correlation with UACR (r=0.27, p<0.005 and urea (r=0.56, p<0.0005) in SCD subjects. NGAL was found to be a good predictor of nephropathy in steady state SCD patients with AUC=0.742, p<0.0001 when compared with creatinine and urea with AUC=0.618, p=0.048 and AUC=0.531, p=0.647 respectively. However, FAR could not be used as a predictive marker since it had non-significant poor performance (AUC=0.462, p=0.536).Conclusion NGAL as independent marker, is an early predictor of kidney disease as compared to urea and creatinine. Fibrinogen-to-albumin ratio can be used to track nephropathy treatment in steady state sickle cell disease patients since it is elevated in those with sickle cell nephropathy compared to healthy individuals. These two markers can be added to the available array of test in the management of nephropathy among steady SCD patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics committee/IRB of Komfo Anokye Teaching Hospital's (KATH IRB/AP/175/23) and Kwame Nkrumah University of Science and Technology's (CHRPE/AP/1037/23) gave approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors